ImmunityBio Inc. (NASDAQ:IBRX) shares are down during Friday’s premarket session. However, there is no news to justify the move.The stock’s decline comes as broader markets experienced a slight downturn, with the Nasdaq falling 0.17% on the previous trading day.Distribution PactOn Thursday, ImmunityBio announced that it has expanded access to its product Anktiva in the EU through a new distribution partnership with Accord Healthcare, which is expected to enhance its market presence.On Wednesday, the European Commission authorized the drug indicated in combination with Bacillus Calmette-Guérin (BCG) for eligible patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease.As part of the partnership, Accord Healthcare will utilize over 100 sales, medical, and marketing professionals to drive the commercialization of Anktiva in the UK, European Union, as well as European Free Trade Association members Iceland, Liechtenstein, ...Full story available on Benzinga.com
ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries
